Atezolizumab significantly improves NSCLC survival vs. standard chemotherapy in Phase III OAK trial Lung, Respiratory and Thoracic Cancer Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
